IAP binding compounds
IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K d of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.
1. A compound represented by formula (5)
or a pharmaceutically acceptable salt thereof
where A 1 is H, or lower alkyl, or A 1 and R 1b together form a ring of 3-5 atoms;
R 1a is H; and R 1b is lower alkyl group, or together with A 1 forms a ring of 3 to 5 atoms;
Y is an alkyl group, an alkynyl group, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of these groups, hydroxy substituted versions of these groups, or Y together with Z 1a , Z 1b , or R 10 forms a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to Z 1a , Z 1b , or R 10 ;
Z 1a and Z 1b are independently an H, hydroxy, amino, alkylamino, diakylamino, alkoxy, aryloxy, or heteroaryloxy group; or Z 1a , Z 1b , together with Y or R 10 form a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Z 1a or Z 1b , is linked to Y or R 10 ;
M is an alkylene group of 1 to 5 carbon atoms;
G is a bond, a heteroatom, —(C═O)—; —NR 18 —; —NCOR 18 —; or —NS(O) x R 18 — where x =0, 1, or 2, and R 18 is lower alkyl, optionally-substituted lower alkyl group; and
R 10 is anyone of structures (4a), (4b), (4c) or (4d):
where X 2 is a nitrogen atom and independently groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are H, optionally-substituted alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups; or groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are contained within a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, and linked to groups at position Y, Z 1a , Z 1b , M, G, R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 .
2. The compound of claim 1 represented by the general formula (5)
or a pharmaceutically acceptable salt thereof
where A 1 is H, or lower alkyl;
R 1a is H; and R 1b is lower alkyl group;
Y is an alkyl group, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of these groups, hydroxy substituted versions of these groups;
Z 1a and Z 1b are independently an H, hydroxy, alkoxy, aryloxy, or heteroaryloxy group;
M is an alkylene group of 1 to 5 carbon atoms;
G is a bond, a heteroatom, or —NCOR 18 — and R 18 is lower alkyl, optionally-substituted lower alkyl group; and
R 10 is anyone of structures (4a), (4b), (4c) or (4d):
where X 2 is a nitrogen atom and independently groups R 11 , R′ 11 , R 12 ,any of R 13-17 , or any of R 14-17 are H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are H, optionally-substituted alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups; or groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are contained within a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, and linked to groups at position Y, Z 1a , Z 1b , M, G, R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 .
3. The compound of claim 1 represented by formula (5)
or a pharmaceutically acceptable salt thereof
where A 1 is H, or methyl;
R 1a is H; and R 1b is methyl or ethyl;
Y is an alkyl group, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of these groups, or hydroxy substituted versions of these groups;
Z 1a and Z 1b are independently an H, hydroxy, or alkoxy group;
M is a methylene group;
G is a bond; and
R 10 is any one of structures (4a) or (4b):
where X 2 is a nitrogen atom and independently groups R 11 , R′ 11 , R 12 , or any of R 14-17 are H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently R 11 , R′ 11 , R 12 , or any of R 14-17 are H, optionally-substituted alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; independently R 11 , R′ 11 , R 12 , or any of R 14-17 are acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups; or groups R 11 , R′ 11 , R 12 , or any of R 14-17 are contained within a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, and linked to groups at position Y, Z 1a , Z 1b , M, G, R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 .
4. The compound of claim 3 or a pharmaceutically acceptable salt thereof, in which R 10 is:
and in which X 2 is a nitrogen atom.
5. The compound of claim 1 or a pharmaceutically acceptable salt thereof that has a K d for an IAP of less than about 1 micromolar.
6. The compound of claim 1 or a pharmaceutically acceptable salt thereof where A 1 is H, methyl, or ethyl.
7. The compound of claim 1 or a pharmaceutically acceptable salt thereof where R 1a is H; and R 1b is methyl or ethyl.
8. The compound of claim 1 or a pharmaceutically acceptable salt thereof where Y is an alkyl group of 1 to 10 carbon atoms, an alkynyl group, a cycloalkyl group of 3 to 7 carbon atoms, optionally substituted versions of these groups, or hydroxy substituted versions of these groups.
9. The compound of claim 1 or a pharmaceutically acceptable salt thereof where Z 1a and Z 1b are independently an H, hydroxy, amino, alkylamino, dialkylamino, alkoxy, aryloxy, or heteroaryloxy group.
10. The compound of claim 1 or a pharmaceutically acceptable salt thereof where R 10 has the structure of formula (4a):
where X 2 is a nitrogen atom and independently groups R 11 , R 12 , or any of R 14-17 is H, or optional substituents including halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy independently R 11 , R 12 , or any of R 14-17 are H, optionally-substituted alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; independently R 11 , R′ 11 , R 12 , or any of R 14-17 are acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups.
11. The compound of claim 1 or a pharmaceutically acceptable salt thereof that has a K d for an IAP of less than about 0.1 micromolar.
12. A compound represented by formula (2):
or a pharmaceutically acceptable salt thereof
wherein: (3*), (4*), (5*) and (6*) indicate potential chiral carbon positions;
A 1 and A 2 are independently hydrogen, alkyl, aryl, or alkylaryl group, R 1a is H or methyl; R 1b is an alkyl or aryl group; X 1 is —O—, —S—, —CH 2 —, or —NH—, and J is —CH—, or —N—, provided that when J is —N—, X 1 is —CH 2 —, or —NH—; Y is H, or an alkyl group; Z is —OH, aryloxy, alkoxy, benzyloxy, benzyloxy, amino, arylamino, alkylamino, or benzylamino group; R 2 is a detectable label or is
M is alkylene, alkenylene, alkynlene, heteroalkylene, heteroalkenylene, or heteroalkynlene group,
G is selected from a bond, —O—; —N(R 2d )— where R 2d is H, alkyl, cycloalkyl, or aryl; or —S(O) m — where m is 0, 1, or 2;
R 10 is anyone of structures (4a), (4b), (4c) or (4d);
where X 2 is a nitrogen atom and independently groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is H, halogen, alkyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are H, optionally-substituted alkyl, aryl, alkenyl, alkynyl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 are acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups and n is independently the integer 0, 1, 2, 3, 4, or 5.
13. A compound represented by formula (3):
or a pharmaceutically acceptable salt thereof
where A 1 is H, lower alkyl, or optionally-substituted lower alkyl group; R 1a and R 1b are separately H, lower alkyl, optionally-substituted lower alkyl, or A 1 together with either R 1a or R 1b form an optionally substituted heterocycloalkyl group of 3 to 6 atoms;
Y is H, an alkyl group, an alkynyl group, a cycloalkyl group of 3 to 7 carbon atoms, aryl, heteroaryl, arylalkyl, optionally-substituted versions of these groups, hydroxy substituted versions of these groups, or Y together with Z, M, G, or R 10 forms a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to Z, M, G, or R 10 ;
Z is H, alkyl, hydroxy, amino, alkylamino, diakylamino, alkoxy, cycloalkyl, cycloalkyloxy, aryl, heteroaryl, aryloxy, or heteroaryloxy group; or Z together with Y, M, G, or R 10 form a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Z is linked to Y, M, G, or R 10 ;
M is alkylene, alkenylene, or alkynylene group of 1 to 5 carbon atoms;
G is a bond, a heteroatom, —(C═O)—; —S(O) t — where t =0, 1, or 2; —NR 18 —; —NCOR 18 —; or —NS(O) x R 18 — where x =0, 1, or 2, and R 18 is lower alkyl, optionally-substituted lower alkyl, or cycloalkyl or R 18 is contained within a carbocyclic, or heterocyclic ring containing 1 to 5 heteroatoms, where R 18 is linked to Z, M, or R 10 ; and
R 10 is any one of structures (4a), (4b), (4c) or (4d):
where X 2 is a nitrogen atom and independently groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; or independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups; or groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is contained within a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, and linked to groups at position Y, Z, M, G, R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 .
14. The compound of claim 13 represented by formula (3):
or a pharmaceutically acceptable salt thereof
where A 1 is H, lower alkyl, or optionally-substituted lower alkyl group; R 1a and R 1b are separately H, lower alkyl, optionally-substituted lower alkyl; or A 1 together with either R 1a or R 1b form an optionally substituted heterocycloalkyl group of 3 to 6 atoms;
Y is H, an alkyl group, an alkynyl group, a cycloalkyl group of 3 to 7 carbon atoms, aryl, heteroaryl, arylalkyl, optionally-substituted versions of these groups, hydroxy substituted versions of these groups, or Y together with Z, M, G, or R 10 forms a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Y is linked to Z, M, G, or R 10 ;
Z is H, alkyl, hydroxy, amino, alkylamino, diakylamino, alkoxy, cycloalkyl, cycloalkyloxy, aryl, heteroaryl, aryloxy, or heteroaryloxy group; or Z together with Y, M, G, or R 10 form a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, where Z is linked to Y, M, G, or R 10 ;
M is an alkylene, alkenylene, or alkynylene group of 1 to 5 carbon atoms;
G is a bond, a heteroatom, —(C═O)—; —S(O) t — where t =0, 1, or 2; —NR 18 —; —NCOR 18 —; or —NS(O) x R 18 — where x =0, 1, or 2, and R 18 is lower alkyl, optionally-substituted lower alkyl, or cycloalkyl or R 18 is contained within a carbocyclic, or heterocyclic ring containing 1 to 5 heteroatoms, where R 18 is linked to Z, M, or R 10 ; and
R 10 is any one of structures (4a), (4b), (4c) or (4d):
where X 2 is a nitrogen atom and independently groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is H, halogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, sulfonate, aryloxy or heteroaryloxy; independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is H, optionally-substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, hydroxyl, alkoxy, polyalkylether, amino, alkylamino, dialkylamino, alkyloxyalkyl, aryloxy, or heteroaryloxy; or independently R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is acyl or acetyl groups, carboxylate, sulfonate, sulfone, imine, or oxime groups; or groups R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 is contained within a carbocyclic ring, or a heterocyclic ring containing 1 to 5 heteroatoms, and linked to groups at position Y, Z, M, G, R 11 , R′ 11 , R 12 , any of R 13-17 , or any of R 14-17 .
15. A composition comprising a compound of claim 13 , 14 , 1 , 2 , 3 , or 4 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
16. The compound of claim 13 , or a pharmaceutically acceptable salt thereof selected from